Attributes | Values |
---|
rdf:type
| |
Description
| - The communication is summarizing results of study aimed to ascertain the efficacy of treatment with epoetin alpha in patients with different hematological disorders and, at the same time to evaluate the impact of this treatment on quality of their lives. Treatment efficacy in separate patients of the monitored population has been evaluated not only according to hemoglobin level increase, but also according to its effect on erythrocyte products consumption needed to control anemic syndrome. Overall 134 patients with different lymphoproliferative disorders were included in the evaluation. Full-extended monitoring, i.e. at least 3-month treatment with epoetin alpha, was passed by 127 (94.8%) patients. Favorable effect of epoetin alpha administration was most often reported in patients with multiple myeloma (85.7%), Waldenstrom's macroglobulinemia (80%) and chronic lymphatic leukemia (76.7%). Conversely the lowest efficacy was reported in the group of patients with myelodysplastic syndrome.
- The communication is summarizing results of study aimed to ascertain the efficacy of treatment with epoetin alpha in patients with different hematological disorders and, at the same time to evaluate the impact of this treatment on quality of their lives. Treatment efficacy in separate patients of the monitored population has been evaluated not only according to hemoglobin level increase, but also according to its effect on erythrocyte products consumption needed to control anemic syndrome. Overall 134 patients with different lymphoproliferative disorders were included in the evaluation. Full-extended monitoring, i.e. at least 3-month treatment with epoetin alpha, was passed by 127 (94.8%) patients. Favorable effect of epoetin alpha administration was most often reported in patients with multiple myeloma (85.7%), Waldenstrom's macroglobulinemia (80%) and chronic lymphatic leukemia (76.7%). Conversely the lowest efficacy was reported in the group of patients with myelodysplastic syndrome. (en)
- Tato práce shrnuje výsledky studie provedené za účelem ověření účinnosti léčby epoetinem alfa u pacientů s různými hematologickými onemocněními a současně zhodnocení dopadu této léčby na jejich kvalitu života. Účinnost léčby byla hodnocena zvýšením krevních hladin hemoglobinu a spotřebou substrátů erytrocyty potřebných ke kontrole anemického syndromu. Studie byla provedena na 134 pacientech s různými lymfoproliferativními onemocněními z nichž 127 bylo monitorováno alespoň 3 měsíce v průběhu terapie epoetinem alfa. Příznivý účinek léčby byl viditelný u pacientů s mnohočetným myelomem (85,7%), Waldenstrőmovou makroglobulinémií (80%) a chronickou lymfatickou leukémií (76,7%). Naopak, nejnižší účinnost byla u pacientů s myelodysplastickým syndromem. (cs)
|
Title
| - Léčba přidružené anémie pomocí epoetinu alfa u různých hematologických onemocnění (cs)
- Treatment of associated anemia in different hematological disorders with epoetin alpha
- Treatment of associated anemia in different hematological disorders with epoetin alpha (en)
|
skos:prefLabel
| - Léčba přidružené anémie pomocí epoetinu alfa u různých hematologických onemocnění (cs)
- Treatment of associated anemia in different hematological disorders with epoetin alpha
- Treatment of associated anemia in different hematological disorders with epoetin alpha (en)
|
skos:notation
| - RIV/00216208:11150/04:00004510!RIV08-MSM-11150___
|
http://linked.open.../vavai/riv/strany
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11150/04:00004510
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - Treatment; associated; anemia; different; hematological; disorders; epoetin; alpha (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| |
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |